Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2021

View Archived Issues

Pyxis Oncology enters worldwide agreement with Pfizer to develop and commercialize novel ADCs

Dyadic plans to conduct first-in-human study of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

The omnivore's dilemma

Dopamine plays role in pain perception sex differences

Reprogrammed cells repair vasculature, brains after stroke

FDA approves Ponvory as oral treatment for adults with relapsing multiple sclerosis

Updated phase Ib data presented for PF-06939926 in boys with DMD

Novel C3 conditional knockout mouse model of AD

Response to tabelecleucel leads to long-term survival in patients with EBV+ PTLD following HCT

UNM Rainforest Innovations patents ER modulators

Korea Institute of Science and Technology divulges protein kinase inhibitors

Etern Biopharma presents new FGFR inhibitors

Janssen Pharmaceutica synthesizes new DHODH inhibitors

Bio-Thera Solutions presents new anti-TIGIT antibodies

Enrollment opens in first-in-human study of mRNA-3927 for propionic acidemia

IMpower010 study of Tecentriq in NSCLC meets DFS primary endpoint

enGene enrolls patients with non-muscle invasive bladder cancer in phase I/II study of EG-70

ARTham Therapeutics provides first phase I data for ART-001 in healthy volunteers

Cellphire initiates phase II study of Thrombosomes for bleeding in patients with thrombocytopenia

Studies identify novel PDAC therapeutic target

AZP-3601 shows promising preliminary data in healthy male subjects

U.S. phase III trial of AZD-1222 for COVID-19 meets primary efficacy endpoint at interim analysis

China NMPA clears start of phase III trial of Endostar for malignant thoracoabdominal effusions

BioAge begins phase II trial of BGE-175 in older patients with COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...